1. Home
  2. BUSE vs ANIP Comparison

BUSE vs ANIP Comparison

Compare BUSE & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Busey Corporation

BUSE

First Busey Corporation

HOLD

Current Price

$27.05

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$81.67

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUSE
ANIP
Founded
1868
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.9B
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
BUSE
ANIP
Price
$27.05
$81.67
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$27.17
$110.00
AVG Volume (30 Days)
467.1K
325.9K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
4.04%
N/A
EPS Growth
N/A
419.23
EPS
0.52
1.28
Revenue
$719,584,000.00
$206,547,000.00
Revenue This Year
$23.84
$21.01
Revenue Next Year
$3.82
$17.59
P/E Ratio
$52.01
$64.04
Revenue Growth
55.66
2.47
52 Week Low
$21.63
$57.34
52 Week High
$27.65
$99.50

Technical Indicators

Market Signals
Indicator
BUSE
ANIP
Relative Strength Index (RSI) 59.87 54.47
Support Level $25.69 $77.32
Resistance Level $27.11 $83.58
Average True Range (ATR) 0.47 3.10
MACD 0.05 -0.01
Stochastic Oscillator 93.85 47.85

Price Performance

Historical Comparison
BUSE
ANIP

About BUSE First Busey Corporation

First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: